CRT 2026

Panel Discussion | What Have We Learned from the Past 30 Years on the Pathophysiology of Cardiogenic Shock?

Moderator(s)

• 

  Maya Guglin, MD

  Director of Heart Failure/Transplant/MCS
  Rutgers University
  Indianapolis, Indiana, United States

  Disclosure(s): No financial relationships to disclose
• 

  Mitchell Krucoff, MD, FACC, FAHA, FSCAI

  Professor Medicine/Cardiology
  Duke University Medical Center/Duke Clinical Research Institute
  Durham, North Carolina, United States

  Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Nipro Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Shockwave/Johnson&Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Terumo Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
• 

  David A. Morrow, MD

  Director, Levine Cardiac Intensive Care Unit
  Brigham and Women's Hospital

  Disclosure(s): 4TEEN4: Grant/Research Support (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Abiomed: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anthos Therapeutics: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Daiichi Sankyo: Grant/Research Support (Ongoing); Merck & Co.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Roche Diagnostics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Panel Discussant(s)

• 

  Anastasios Apostolos, MD, MSc, PhDc

  Clinical Fellow in Cardiology
  Department of Cardiology, Harefield Hospital, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London; First Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Hippocration Hospital, Athens, Greece
  London, England, United Kingdom

  Disclosure(s): No financial relationships to disclose
• 

  Spencer D. Liu, MD

  Interventional Heart Failure Cardiologist, Assistant Professor
  Northwell Health - Staten Island University Hospital

  Disclosure(s): No financial relationships to disclose
• 

  Jacob Eifer Møller, MD

  Consultant
  Rigshospitalet Copenhagen Denmark

  Disclosure(s): Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Magenta,: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Srihari S. Naidu, MD, MSCAI

  Director, Cath Labs and HCM Program
  Westchester Medical Center
  Valhalla, New York, United States

  Disclosure(s): No financial relationships to disclose
• 

  Michael J. Rinaldi, MD

  Director Structural Heart Program
  Sanger Heart and Vascular Institute/Atrium Health
  Charlotte, North Carolina, United States

  Disclosure(s): PiCardia: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Catalin Toma, MD

  Associate Professor
  University of Pittsburgh Medical Center , Pennsylvania, United States

  Disclosure information not submitted.